Akero Therapeutics, Inc. (AKRO)

20.08 +0.19 (+0.96%) At close: 04:00PM EDT

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://akerotx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 55

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Andrew Cheng M.D., Ph.D.	President, CEO & Director	1.04M	15.28M	1967
Dr. Jonathan M. Young J.D., Ph.D.	Co-Founder, Executive VP, COO & Secretary	672.35k	584.34k	1970
Dr. Timothy Rolph	Co-Founder & Chief Scientific Officer	722.32k	2.16M	1954
Mr. William R. White J.D.	Executive VP, CFO, Treasurer & Head of Corporate Development	678.06k	839.84k	1973
Ms. Catriona Yale	Executive VP & Chief Development Officer	678.06k	458.9k	1972
Mr. Patrick Lamy	Senior Vice President of Commercial Strategy	N/A	N/A	1973
Mr. John J. Schembri	VP of Finance & Controller	N/A	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate governance

Akero Therapeutics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.